| Market Overview
The global OTC Artificial Tears Market size reached USD 5.4 Billion in 2024. The market is expected to reach USD 8.0 Billion by 2033, growing at a CAGR of 4.4% during the forecast period of 2025-2033. OTC artificial tears are biocompatible eye drops used to lubricate and provide relief from eye discomforts such as pain, burning, and redness. They are available in various forms including solution, ointment, emulsion, gel, and spray solution. The product is increasingly adopted due to rising dry eye syndrome prevalence, electronic device usage, and product innovations. Study Assumption Years
• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033 OTC Artificial Tears Market Key Takeaways
• The global OTC artificial tears market size was USD 5.4 Billion in 2024.
• The market is projected to grow at a CAGR of 4.4% during 2025-2033.
• The forecast period for the market growth is from 2025 to 2033.
• Rising geriatric population prone to chronic eye disorders drives growth.
• Increasing dry eye syndrome (DES), diabetes, and nutritional deficiencies raise demand.
• Growing screen time from electronic devices contributes to eye fatigue and product adoption.
• Product innovations like blink-activated coatings enhance market expansion.
• Widespread use with contact lenses prevents eye dryness and promotes oxygen flow. Sample Request Link:
https://www.imarcgroup.com/Otc-Artificial-Tears-Market/requestsample Market Growth Factors
Increase in the geriatric population susceptible to chronic eye diseases is a major growth driver of the chronic eye disease treatment market. Chronic eye disorders are more common in old population and there is an increase in the prevalence of dry eye syndrome (DES), diabetes, and nutritional deficiency that causes eye discomfort, burning and redness. This demographic trend seems to be fueling global market growth in general. More daily usage of digital devices including smartphones, television, and laptops leads to more exposure to screen time. This results in digital eye strain with dry eye symptoms. Hence, the increase in the usage of OTC artificial tears among end-users who prefer immediate relief from eye strain is expected to drive the market during the forecast period. Improvements to product formulations, such as the development of products with blink-activated coatings to improve ocular moisture, are contributing to the growing market for treatments for dry eye. Artificial tears can also be used with contact lenses, as they can be designed to allow oxygen to pass through to the cornea and minimize dryness on the corneal surface. Market Segmentation Product
• Solution
• Ointment
• Emulsion
• Gel
• Spray Solution
• Suspensions Solutions currently hold the majority share due to their convenient form and widespread use. Container Type
• Plastic Single Dose Container
• Plastic Multi-Dose Container
• Others Plastic multi-dose containers exhibit clear dominance in the market due to user convenience and cost-effectiveness. Formulation
• Preservative Based
• Non-Preservative Based Preservative based formulations currently hold the majority of the global market share. Application
• Dry Eye Syndrome
• Allergies
• Infections
• UV and Blue Light Protection
• Contact Lens Moisture Retention
• Others Dry eye syndrome accounts for the largest share given its high prevalence. Distribution Channel
• Hospital Pharmacies
• Drug Store and Retail Pharmacies
• Online Pharmacies Drug store and retail pharmacies currently dominate the market as primary purchase points. Regional Insights
North America dominates the global OTC artificial tears market, benefiting from high product adoption, awareness, and advanced healthcare infrastructure. The region’s dominance is supported by a growing elderly population susceptible to eye conditions and strong retail pharmacy networks facilitating easy accessibility. Key Players
• AbbVie Inc.
• Alcon
• Bausch and Lamb
• Jawa Pharmaceuticals Pvt. Ltd.
• OASIS Medical, Inc.
• OcuSoft
• Rohto Eye Drops
• Scope Ophthalmics Ltd.
• Sentiss Pharma Pvt. Ltd.
• Thea Pharmaceuticals Limited
• Ursapharm Arzneimittel GmbH If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization. Request For Customization: https://www.imarcgroup.com/request?type=report&id=4958&flag=E About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research. Contact Us
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302 | 